This article was originally published in Start Up
Atherogenics Inc. has begun clinical trials on a compound that goes to the heart of the matter by attacking the inflammation processes that can cause atherosclerosis and the build-up of plaque.
You may also be interested in...
Companies pursuing small-molecule drugs are by far the most popular of the start-ups in biopharmaceuticals. But the biggest opportunity in the business is still up for grabs: the industrialization of medicinal chemistry.
Wound Solutions Ltd. looks to the paradigm of patient self-care in diabetes to address the gaps in chronic wound care, where the feedback provided by blood glucose monitoring encourages changes in behavior. A small device that is placed under a compression bandage helps patients with venous leg ulcers comply with the steps they should be taking to support wound healing, in the process, collecting data that helps clinicians make informed therapy decisions.
The treatment of chronic wounds is challenging, not only because of the underlying biology, but also because of more practical considerations: fragmentation in the care settings, the logistics of delivering products to patients, and the costs of chronic care. Next generation advanced wound care companies are engineering solutions to these problems.